Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era

Fuu Jen Tsai, Chi Fung Cheng, Chih Ho Lai, Yang Chang Wu, Mao Wang Ho, Jen Hsien Wang, Ni Tien, Xiang Liu, Hsinyi Tsang, Ting Hsu Lin, Chiu Chu Liao, Shao Mei Huang, Ju Pi Li, Jung Chun Lin, Chih Chien Lin, Jin Hua Chen, Wen Miin Liang, Ying Ju Lin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

HIV-infected patients exposed to antiretroviral therapy (ART) have an increased risk for hyperlipidemia and cardiovascular disease. We performed a longitudinal, comprehensive, and population-based study to investigate the cumulative effect of different types of ART regimens on hyperlipidemia risk in the Taiwanese HIV/ART cohort. A total of 13,370 HIV-infected patients (2,674 hyperlipidemia and 10,696 non-hyperlipidemia patients) were recruited after matching for age, gender, and the first diagnosis date of HIV infection by using the National Health Insurance Research Database in Taiwan. Hyperlipidemia risk associated with cumulative ART use, ART adherence, and their combination was assessed. The matched hyperlipidemia group had a larger number of patients using ART and a higher incidence of comorbidities, specifically, respiratory disease and diabetes. Patients with high ART dosage and dose-dependent manner adherence, respectively, demonstrated an increased risk of hyperlipidemia. For single ART regimens, patients receiving nucleoside reverse-transcriptase inhibitors (NRTI/NRTI)- containing regimen had the highest hyperlipidemia risk, followed by protease inhibitor (PI)- containing and non-NRTIwww containing regimens. For combination ART regimens, patients receiving a NRTI/NRTI + PI regimen had the highest hyperlipidemia risk. An increased cumulative drug dose was observed in patients who received the PI, NRTI/NRTI, NRTI, and NNRTI regimens in the hyperlipidemia group, when compared to the non-hyperlipidemia group. In conclusion, ART cumulative use, adherence, and regimen may affect hyperlipidemia risk among HIV-infected patients in a dose-dependent manner.

Original languageEnglish
Pages (from-to)106369-106381
Number of pages13
JournalOncotarget
Volume8
Issue number63
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Highly Active Antiretroviral Therapy
Hyperlipidemias
HIV
Protease Inhibitors
Therapeutics
Reverse Transcriptase Inhibitors
National Health Programs
Taiwan
Nucleosides
HIV Infections
Comorbidity
Research Design
Cardiovascular Diseases
Databases
Incidence

Keywords

  • Antiretroviral therapy
  • HIV
  • Hyperlipidemia
  • Nucleoside reverse-transcriptase inhibitor
  • Protease inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era. / Tsai, Fuu Jen; Cheng, Chi Fung; Lai, Chih Ho; Wu, Yang Chang; Ho, Mao Wang; Wang, Jen Hsien; Tien, Ni; Liu, Xiang; Tsang, Hsinyi; Lin, Ting Hsu; Liao, Chiu Chu; Huang, Shao Mei; Li, Ju Pi; Lin, Jung Chun; Lin, Chih Chien; Chen, Jin Hua; Liang, Wen Miin; Lin, Ying Ju.

In: Oncotarget, Vol. 8, No. 63, 01.01.2017, p. 106369-106381.

Research output: Contribution to journalArticle

Tsai, FJ, Cheng, CF, Lai, CH, Wu, YC, Ho, MW, Wang, JH, Tien, N, Liu, X, Tsang, H, Lin, TH, Liao, CC, Huang, SM, Li, JP, Lin, JC, Lin, CC, Chen, JH, Liang, WM & Lin, YJ 2017, 'Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era', Oncotarget, vol. 8, no. 63, pp. 106369-106381. https://doi.org/10.18632/oncotarget.22465
Tsai, Fuu Jen ; Cheng, Chi Fung ; Lai, Chih Ho ; Wu, Yang Chang ; Ho, Mao Wang ; Wang, Jen Hsien ; Tien, Ni ; Liu, Xiang ; Tsang, Hsinyi ; Lin, Ting Hsu ; Liao, Chiu Chu ; Huang, Shao Mei ; Li, Ju Pi ; Lin, Jung Chun ; Lin, Chih Chien ; Chen, Jin Hua ; Liang, Wen Miin ; Lin, Ying Ju. / Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era. In: Oncotarget. 2017 ; Vol. 8, No. 63. pp. 106369-106381.
@article{074fd166a863420d9ba267cc12cbab74,
title = "Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era",
abstract = "HIV-infected patients exposed to antiretroviral therapy (ART) have an increased risk for hyperlipidemia and cardiovascular disease. We performed a longitudinal, comprehensive, and population-based study to investigate the cumulative effect of different types of ART regimens on hyperlipidemia risk in the Taiwanese HIV/ART cohort. A total of 13,370 HIV-infected patients (2,674 hyperlipidemia and 10,696 non-hyperlipidemia patients) were recruited after matching for age, gender, and the first diagnosis date of HIV infection by using the National Health Insurance Research Database in Taiwan. Hyperlipidemia risk associated with cumulative ART use, ART adherence, and their combination was assessed. The matched hyperlipidemia group had a larger number of patients using ART and a higher incidence of comorbidities, specifically, respiratory disease and diabetes. Patients with high ART dosage and dose-dependent manner adherence, respectively, demonstrated an increased risk of hyperlipidemia. For single ART regimens, patients receiving nucleoside reverse-transcriptase inhibitors (NRTI/NRTI)- containing regimen had the highest hyperlipidemia risk, followed by protease inhibitor (PI)- containing and non-NRTIwww containing regimens. For combination ART regimens, patients receiving a NRTI/NRTI + PI regimen had the highest hyperlipidemia risk. An increased cumulative drug dose was observed in patients who received the PI, NRTI/NRTI, NRTI, and NNRTI regimens in the hyperlipidemia group, when compared to the non-hyperlipidemia group. In conclusion, ART cumulative use, adherence, and regimen may affect hyperlipidemia risk among HIV-infected patients in a dose-dependent manner.",
keywords = "Antiretroviral therapy, HIV, Hyperlipidemia, Nucleoside reverse-transcriptase inhibitor, Protease inhibitor",
author = "Tsai, {Fuu Jen} and Cheng, {Chi Fung} and Lai, {Chih Ho} and Wu, {Yang Chang} and Ho, {Mao Wang} and Wang, {Jen Hsien} and Ni Tien and Xiang Liu and Hsinyi Tsang and Lin, {Ting Hsu} and Liao, {Chiu Chu} and Huang, {Shao Mei} and Li, {Ju Pi} and Lin, {Jung Chun} and Lin, {Chih Chien} and Chen, {Jin Hua} and Liang, {Wen Miin} and Lin, {Ying Ju}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22465",
language = "English",
volume = "8",
pages = "106369--106381",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "63",

}

TY - JOUR

T1 - Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era

AU - Tsai, Fuu Jen

AU - Cheng, Chi Fung

AU - Lai, Chih Ho

AU - Wu, Yang Chang

AU - Ho, Mao Wang

AU - Wang, Jen Hsien

AU - Tien, Ni

AU - Liu, Xiang

AU - Tsang, Hsinyi

AU - Lin, Ting Hsu

AU - Liao, Chiu Chu

AU - Huang, Shao Mei

AU - Li, Ju Pi

AU - Lin, Jung Chun

AU - Lin, Chih Chien

AU - Chen, Jin Hua

AU - Liang, Wen Miin

AU - Lin, Ying Ju

PY - 2017/1/1

Y1 - 2017/1/1

N2 - HIV-infected patients exposed to antiretroviral therapy (ART) have an increased risk for hyperlipidemia and cardiovascular disease. We performed a longitudinal, comprehensive, and population-based study to investigate the cumulative effect of different types of ART regimens on hyperlipidemia risk in the Taiwanese HIV/ART cohort. A total of 13,370 HIV-infected patients (2,674 hyperlipidemia and 10,696 non-hyperlipidemia patients) were recruited after matching for age, gender, and the first diagnosis date of HIV infection by using the National Health Insurance Research Database in Taiwan. Hyperlipidemia risk associated with cumulative ART use, ART adherence, and their combination was assessed. The matched hyperlipidemia group had a larger number of patients using ART and a higher incidence of comorbidities, specifically, respiratory disease and diabetes. Patients with high ART dosage and dose-dependent manner adherence, respectively, demonstrated an increased risk of hyperlipidemia. For single ART regimens, patients receiving nucleoside reverse-transcriptase inhibitors (NRTI/NRTI)- containing regimen had the highest hyperlipidemia risk, followed by protease inhibitor (PI)- containing and non-NRTIwww containing regimens. For combination ART regimens, patients receiving a NRTI/NRTI + PI regimen had the highest hyperlipidemia risk. An increased cumulative drug dose was observed in patients who received the PI, NRTI/NRTI, NRTI, and NNRTI regimens in the hyperlipidemia group, when compared to the non-hyperlipidemia group. In conclusion, ART cumulative use, adherence, and regimen may affect hyperlipidemia risk among HIV-infected patients in a dose-dependent manner.

AB - HIV-infected patients exposed to antiretroviral therapy (ART) have an increased risk for hyperlipidemia and cardiovascular disease. We performed a longitudinal, comprehensive, and population-based study to investigate the cumulative effect of different types of ART regimens on hyperlipidemia risk in the Taiwanese HIV/ART cohort. A total of 13,370 HIV-infected patients (2,674 hyperlipidemia and 10,696 non-hyperlipidemia patients) were recruited after matching for age, gender, and the first diagnosis date of HIV infection by using the National Health Insurance Research Database in Taiwan. Hyperlipidemia risk associated with cumulative ART use, ART adherence, and their combination was assessed. The matched hyperlipidemia group had a larger number of patients using ART and a higher incidence of comorbidities, specifically, respiratory disease and diabetes. Patients with high ART dosage and dose-dependent manner adherence, respectively, demonstrated an increased risk of hyperlipidemia. For single ART regimens, patients receiving nucleoside reverse-transcriptase inhibitors (NRTI/NRTI)- containing regimen had the highest hyperlipidemia risk, followed by protease inhibitor (PI)- containing and non-NRTIwww containing regimens. For combination ART regimens, patients receiving a NRTI/NRTI + PI regimen had the highest hyperlipidemia risk. An increased cumulative drug dose was observed in patients who received the PI, NRTI/NRTI, NRTI, and NNRTI regimens in the hyperlipidemia group, when compared to the non-hyperlipidemia group. In conclusion, ART cumulative use, adherence, and regimen may affect hyperlipidemia risk among HIV-infected patients in a dose-dependent manner.

KW - Antiretroviral therapy

KW - HIV

KW - Hyperlipidemia

KW - Nucleoside reverse-transcriptase inhibitor

KW - Protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85036613370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036613370&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22465

DO - 10.18632/oncotarget.22465

M3 - Article

AN - SCOPUS:85036613370

VL - 8

SP - 106369

EP - 106381

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 63

ER -